

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 5553

Title: Advances in radiotherapy and targeted therapies for rectal cancer.

Reviewer code: 00646322

Science editor: Song, Xiu-Xia

Date sent for review: 2013-09-15 16:17

Date reviewed: 2013-09-28 00:05

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of	<input type="checkbox"/> No records	
<input type="checkbox"/> Grade D (Fair)	language polishing	BPG Search:	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

The manuscript represents a review of current advances in radiotherapy and targeted therapies for rectal cancer. An interesting role of arginase-1 overexpressed in myeloid-derived suppressor cells in balancing between pro-tumor and anti-tumor effects of immune system on cancer is discussed. The review underlines the importance of integrating the genetic and immune biomarkers for making a decision on the types and the doses of the therapies.

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 5553

Title: Advances in radiotherapy and targeted therapies for rectal cancer.

Reviewer code: 00097113

Science editor: Song, Xiu-Xia

Date sent for review: 2013-09-15 16:17

Date reviewed: 2013-10-05 03:21

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input checked="" type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	language polishing	BPG Search:	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

The section on targeted therapies could be extended a little bit, to include comments on additional cell membrane receptors (e.g., GPCRs?) and protein kinase pathways, as well as other mechanisms (e.g., epigenetics) currently under investigation as therapeutic targets.